A single-arm, open-label, phase II clinical trial was conducted to evaluate the superiority and safety of neoadjuvant treatment with kadunilumab in resectable duodenal adenocarcinoma with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR)

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 41f74b30275ee806c65d4c820153289cb486d422
First added on: Apr 05, 2025